Neural Therapeutics Inc. NURL
CNSX
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 52.33% | -89.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.75% | -89.11% | |||
| Operating Income | -47.75% | 89.11% | |||
| Income Before Tax | -506.02% | -137.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -506.02% | -137.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -506.02% | -137.11% | |||
| EBIT | -47.75% | 89.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -500.00% | -121.43% | |||
| Normalized Basic EPS | -450.00% | 92.86% | |||
| EPS Diluted | -500.00% | -121.43% | |||
| Normalized Diluted EPS | -450.00% | 92.86% | |||
| Average Basic Shares Outstanding | 0.00% | 77.05% | |||
| Average Diluted Shares Outstanding | 0.00% | 77.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||